PGC-1 : Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-Alpha
Plant Cell Environ
In vivo, BPC-157 demonstrates robust efficacy in rodent models, accelerating healing of skin wounds, muscle tears, tendon and ligament injuries, and gastrointestinal ulcers
Adding active ingredients during this phase reduces that protection
To move Epitalon from experimental to evidence-based, several developments are essential: Randomized, double-blind, placebo-controlled clinical trials, ideally targeting specific endpoints (sleep, immune aging, telomere attrition) Toxicology and long-term safety studies, including exploration of stereoisomer effects and off-target consequences Validated delivery systems (e.g., dendrimer-conjugates, transdermal patches) that make real-world use feasible Pharmacodynamic biomarkers, to identify responders and track efficacy objectively over time Epitalon is not snake oil, but its also not a magic bullet